VistaGen Therapeutics VTGN shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.
The company said long-term intranasal administration of fasedienol up to four times per day in daily life was safe and well-tolerated in nearly 500 social anxiety disorder (SAD) patients.
Analysis of the final data set showed Fasedienol demonstrated clinically meaningful functional improvement.
"We believe these data suggest that studies involving multiple administrations of fasedienol over time, on an as-needed basis at moments when subjects experience real-life, socially stressful situations, most accurately demonstrate the safety and efficacy potential of fasedienol in patients with SAD and reflect the way we believe fasedienol would be used by SAD patients, if approved,” said Shawn Singh, CEO of Vistagen.
Vistagen is a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders.
Price Action: Vistagen has a 52-week high of $1.79 and a 52-week low of $0.08.
Vistagen shares are up 13.6% at $0.15 at the time of writing, according to Benzinga Pro.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
